welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy

key information

study id #: NCT01826474

condition: Duchenne Muscular Dystrophy

status: terminated


The purpose of the study is to see whether PRO045 is safe and effective to use as medication for Duchenne Muscular Dystrophy (DMD) patients with a mutation around location 45 in the DNA for the dystrophin protein.

PRO045, 0.15 mg/kg/week, PRO045, 1.0 mg/kg/week, PRO045, 3.0 mg/kg/week, PRO045, 6.0 mg/kg/week, PRO045, 9.0 mg/kg/week, PRO045, selected dose

mechanism of action: Exon-skipping to promote dystrophin production

results: https://clinicaltrials.gov/ct2/show/results/NCT01826474

last updated: November 21, 2018